Midmark, eClinicalWorks complete product integration

Jeff Byers | | Health Exec | Digital Transformation
Diagnostic device company Midmark has completed the integration of its Midmark IQstress system with health IT company eClinicalWorks.

eClinicalWorks EMR users can now add Midmark’s IQstress to the list of available digital diagnostic products integrated into their EMR, which includes the Versailles, Ohio-based Midmark’s IQECG and IQspiro.

The Midmark IQstress system includes a digital ECG, integrated stress analysis software, stress cart and a medical grade treadmill, according to eClinicalWorks, of Westborough, Mass. IQstress is offered in two configurations – for the office that has a computer system in place or as a turn-key system with a computer, monitor and printer, eClinicalWorks said.

Jeff Byers

Related Content

From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
ICU diary-keeping: There’s an AI for that
Stanford HAI lookback: Best-read blog posts of 2024
Providers, payers share actionable experiences involving healthcare AI
Healthcare-specific AI: How to multiply successes and head off accidents

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.